
Between May 12 and June 3, Oncothyreon's stock price rose 183%, best among all the companies presenting cancer drug research at the American Society of Clinical Oncology annual meeting.
05
Juin2015
Between May 12 and June 3, Oncothyreon's stock price rose 183%, best among all the companies presenting cancer drug research at the American Society of Clinical Oncology annual meeting.
"Nous gérons cinq fonds de capital-risque consacrés au secteur de l'innovation, qui englobe les secteurs du numérique mais aussi la biotech, "
France Biotech, l'association des Entrepreneurs des Science de la Vie, vient d'annoncer les sociétés et les partenaires qui participeront à la 2ème édition des « French Life Science Days », évènement majeur qui réunit les sociétés françaises cotées biotech, medtech et cleantech et les investisseurs spécialisés américains.
Prana Biotechnology Limited a annoncé aujourd'hui que la Commission européenne avait approuvé la désignation orpheline pour le PBT2 dans le... | 1 juin 2015
PARIS, 3 juin (Reuters) - L action Innate Pharma reprend le chemin de la hausse mercredi alors que le titre de la société de biotechnologie en avait perdu en début de semaine...
André Choulika does not mince words. The Cellectis CEO is an outspoken champion of all things related to the company he founded 15 years ago.
Axovant Sciences, heading toward Phase III with an ex-GlaxoSmithKline treatment for Alzheimer's disease, has upped its IPO hopes to more than $300 million, betting it can win FDA approval where many others have failed.
LUND, Sweden, June 1, 2015 -- Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that the company has made a notification of planned redundancies of 47 of its employees, which means a...
"The collaboration will draw on L’Oreal’s experience in beauty product development and Organovo’s proprietary NovoGen Bioprinting Platform to grow bioprinted skin for product testing."
Puma Biotechnology, Inc. , a development stage biopharmaceutical company, announced the presentation of positive results from the Phase III clinical trial of Puma's investigational drug PB272 for the extended adjuvant treatment of breast cancer .